Form 4: Sutro Biopharma Director Acquires Stock Options

Sutro Biopharma Director Connie Matsui acquired 10,000 stock options with an exercise price of $26.09.

Summary

• Director Connie Matsui acquired 10,000 stock options for Sutro Biopharma, Inc. (STRO).
• The options have an exercise price of $26.09 and were acquired on June 5, 2026.
• These options are exercisable starting June 5, 2026, and expire on June 5, 2036.
• The options vest monthly, with 8.33% of the total award vesting each month, starting July 5, 2026.
• Full vesting is expected by the issuer's 2027 annual stockholders meeting or June 5, 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard grant of stock options to a director, indicating long-term alignment rather than immediate financial performance.

Positives

• Director Connie Matsui has acquired a significant number of stock options, indicating confidence in the company's future.
• The acquisition of options with a strike price of $26.09 suggests a belief that the stock price will exceed this level.

Future Outlook

The vesting schedule and expiration date of the stock options suggest a long-term outlook for the company, with full vesting expected within approximately one year and exercisability extending for ten years.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biopharmaceutical industry, often used as a long-term incentive to align management's interests with those of shareholders and to reward performance.

Stakeholder Impact

• Shareholders: The acquisition of options by a director can be seen as a positive signal of commitment and belief in the company's future growth, potentially aligning director incentives with shareholder value.

Next Steps

• The stock options will vest monthly starting July 5, 2026.
• The options will be fully vested and exercisable by June 5, 2027, or the date of the issuer's 2027 annual stockholders meeting, whichever is earlier.
• The options expire on June 5, 2036.

Key Dates

Keywords

Sutro Biopharma, STRO, Form 4, Stock Options, Insider Trading, Director, SEC Filing, Beneficial Ownership